Mikhail Blagosklonny is Professor of Oncology at Roswell Park Cancer Institute in Buffalo, the only comprehensive cancer center in upstate New York. Prior to his appointment at Roswell Park, he taught at New York Medial College and was a researcher at Ordway Research Institute in Albany. Before moving to the United States, Dr. Blagosklonny completed his medical education at First Pavlov Medical University in St. Petersburg, Russia, and later completed a PhD in Experimental Medicine at the same institution.
Dr. Mikhail Blagosklonny is keenly interested in the anti-aging process and the possibility of using healthy cells from becoming cancerous. He also researches targeted cancer therapies. He is perhaps best known for his work on the role of TOR signaling in aging and is researching the potential of using the cancer drug Rapamycin to extend lifespans. In addition to his research activities, Dr. Blagosklonny is active in academic publishing as the editor in chief of several academic journals, including Oncotarget.
Oncotarget is a weekly venue that was established in 2010. The journal is both open-access and peer-reviewed. Although the journal welcomes submissions on all aspects of cancer research and oncology, the publication specializes in new and innovative therapies. Dr. Blagonsklonny is also the editor in chief of the jounral Aging Cell Cycle at https://www.researchgate.net/profile/Mikhail_Blagosklonny.
Much of Dr. Blagonsklonny’s research centers on the mechanisms of human aging. In 2012, he published a groundbreaking article on Wikipedia.org in which he questions the conventional wisdom that aging is a continuous process that begins at birth and occurs due to accumulated molecular damage that the body cannot repair in time. Instead, he put forth the hyper-function theory, which argues that the same pathway responsible for human development during puberty and adolescence is also responsible for aging, explaining why older children have a lower mortality rate than infants.